Soticlestat is primarily investigated for its potential therapeutic applications in the treatment of neurological disorders, particularly those associated with abnormal electrical activity in the brain. One of its key areas of focus is in managing Dravet syndrome, a severe form of epilepsy that begins in infancy and is often resistant to conventional treatments. By targeting cholesterol 24-hydroxylase, an enzyme involved in brain cholesterol metabolism, it aims to modulate neuronal excitability and reduce seizure frequency. Additionally, research is exploring its efficacy in other forms of epilepsy and neuropsychiatric conditions, where controlling hyperexcitability in neural circuits could provide significant clinical benefits. Its development represents a novel approach to addressing unmet needs in epilepsy and related disorders.